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FOREWORD
NAVIGATING UNCHARTED WATERS: INTELLECTUAL
PROPERTY RIGHTS SURROUNDING GENOMICS RESEARCH &
DEVELOPMENT INFORMATION
LAWRENCE M. SUNG, J.D., Ph.D.*
The completion of a working draft of the human genome sequence two years
ago will, no doubt, prove to be an integral chapter in a story of extraordinary
technological achievement- a story based on the continued revelation of genetic
information. The story, however, is unfinished and the outcome is uncertain.
Many issues have yet to be addressed, in particular, the question of access.
There is a vast amount of genetic data being generated through the efforts of
various public and private research institutions. Who is allowed access to the
genetic data? Who regulates this access? Who pays for and who benefits from
such access? The answers to these questions must be answered before the rest of
the story can be written.
On October 21, 2002, the Intellectual Property Law Program and The Law
and Health Care Program of the University of Maryland School of Law co-hosted
an interdisciplinary symposium entitled, "At the Crossroads-Public/Private
Priorities Concerning Access to Genetic Information." This conference focused on
the business, legal, scientific and social implications of regulating access to genetic
data. In addition, the symposium provided a forum to explore the development of
a consensus model for balancing the benefits of free and unfettered public access to
genetic information with those of protecting private investment-backed
expectations regarding genetic research. The program drew from the combined
insights of international scholars in molecular genetics and bioinformatics,
intellectual property law, and bioethics, as well as from various perspectives of
leaders in the biotechnology industry.
* Assistant Profesor of Law, University of Maryland School of Law (Baltimore, MD); J.D., cum laude,
The American University, Washington College of Law (Washington, D.C.); Ph.D. Microbiology,
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MD); B.A. Biology, University of Pennsylvania (Philadelphia, PA). Former judicial clerk to the
Honorable Raymond C. Clevenger, III, The United States Court of Appeals for the Federal Circuit
(Washington, D.C.). Please direct all inquiries and/or comments by telephone to 410.706.1052,
facsimile at 410.706.2184, or e-mail at lsung@law.umaryland.edu.
NAVIGATING UNCHARTERED WATERS
I. HUMANITY'S GREATEST GIFT PRESENTS HUMANITY'S GREATEST CHALLENGE
Scientists' ability to unmask nature's design, through the automated
sequencing of the genetic code using evolving techniques, continues to capture the
media spotlight. Indeed, the endeavor to understand the human condition, which is
fueled by the desire to enhance and prolong life, marks each year with discoveries
of great significance. On February 21, 2001, the world awoke to the defining news
that a milestone in genetic knowledge was achieved, which is arguably unrivaled
by any other previous announcement.1 The scientific research teams dedicated to
deciphering the precise structural nature of the chemicals that encode the design of
the human organism announced the release of their long anticipated findings- the
2nucleotide sequence of the human genome.
1. See, e.g., Early Edition: Scientists Set to Announce Major Advances in Mapping the Human
Genome (CNN television broadcast, Feb. 12, 2001), LEXIS, News Library, Transcripts ("[I]n just three
hours, we're going to hear what could be the beginning of a revolution in the practice of medicine. An
announcement regarding the mapping of all the genes in the human body will be made in
Washington."); Today: Human Genome Decoded (NBC television broadcast, Feb. 12, 2001), LEXIS,
News Library, Transcripts ("This morning details on what may be the most amazing scientific
accomplishment ever, the mapping of the human genome. Last June, scientists on competing teams
announced they had done it, and today they are releasing their results, and it could revolutionize the
future of medical care."); World News This Morning: Map of Human Genome Debuts with Some Big
Surprises (ABC television broadcast, Feb. 12, 2001), LEXIS, News Library, Transcripts ("History will
have to judge, of course, but scientists say they may be at a turning point comparable to Copernicus
figuring out the layout of the solar system or Darwin beginning to understand how plants and animals
evolved."); The Early Show: Two Rival Studies Offer the First Detailed Look at Most of the Human
Genetic Code (CBS television broadcast, Feb. 12, 2001), LEXIS, News Library, Transcripts ("We've
been trying in the 20th century to try to treat disease without even knowing what the parts were, without
knowing what was wrong in diseases like diabetes or asthma or hypertension. It'd be like bringing your
car to an auto mechanic who didn't know what was under the hood, didn't know the parts."); see also
Clive Cookson, A Glimpse of the Secrets of Life: The Results of the Human Genome Project Show
Unexpected Layers of Complexity in our Genes, FIN. TIMES (London), Feb. 12, 2001, at 21, LEXIS,
News Library, Major World Newspapers ("Eight months ago, Bill Clinton and Tony Blair linked up to
proclaim one of science's greatest achievements: decoding the human genome or 'book of life.' But
that public relations spectacular was not supported by research data or conclusions. This week
scientists get their first look at the evidence, with the official publication of the human genome
sequence in the journals Nature and Science."); China on Par with Developed Countries in Genome
Research: Experts, XNHUA NEWS AGENCY (Beijing), Feb. 12, 2001, LEXIS, News Library, Beyond
Two Years ("The latest map and preliminary conclusion on the human genome by experts from China
and five developed countries indicate China is on a par with the developed countries in this field ....
[T]he progress, unveiled late Monday by international sciences news weekly Science and Natiire, is the
result of international cooperation. The research demonstrates the strength of China, the only
developing country allowed to join the project, in this advanced research field .... ").
2. See Elizabeth Pennisi, The Human Genome, 291 SC1. 1177, 1178 (2001) ("Just obtaining the
sequence is a phenomenal achievement, one that many researchers did not believe possible 15 years ago
.... Spelling out the entire sequence, all 3 billion or so chemical letters that make up DNA along each
chromosome would fill tomes equivalent to 200 New York City phone books .... Perhaps most
humbling of all is the finding.., that humans have 32,000 genes, give or take a few thousand.").
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For even the most casual observers, the accomplishment underlying this
report was earthshaking.3 Even for those who had closely monitored the progress
of this project throughout its years of intensive effort, the publication of the human
genome sequence was no less heralded. Indeed, the editors of Science, one of the
two leading scientific journals, pronounced it a "historic moment for the scientific
endeavor. 'A The message to the scientific community, however, also appeared to
reflect a tenor of underlying concern.
Humanity has been given a great gift. With the completion of the
human genome sequence, we have received a powerful tool for
unlocking the secrets of our genetic heritage and for finding our place
among the other participants in the adventure of life . ... It should be
no surprise that an achievement so stunning, and so carefully watched,
has created new challenges for the scientific venture.5
The process of the discovering of our genetic code, from its inception, has
fostered coincident public scrutiny and concern, which included portents of privacy
loss, genetic discrimination and eugenics. 6 Perhaps most controversial, however,
are the issues of ownership and exclusivity obtainable, through patent protection,
to aspects of the human genome.7 The public debate aside, the federal courts,
3. See Leslie Roberts, Controversial from the Start, 291 Sci. 1182, 1182 (2001) ("The human
genome: the crown jewel of 20th century biology, heralded at the White House, plastered on the covers
of countless magazines-and at last spelled out today in intricate detail in both Science and Nature.
Deciphering this string of 3 billion A's, T's, G's, and C's is being hailed as an achievement that will
usher in a new era of biology and even alter our understanding of who we are.").
4. See Barbara R. Jasny & Donald Kennedy, The Human Genome, 291 SCI. 1153, 1153 (2001)
(commemorating the contemporaneous publications of the human genome sequence in Science by J.
Craig Venter et al. of Celera Genomics, a private enterprise, and in Nature by the International Human
Genome Sequencing Consortium, a publicly-funded international cooperative of laboratories led by
Francis Collins).
5. See id. (indicating, as important considerations, aspects of "access to all the data needed to
verify conclusions" and "protection against piracy... [to] enable other proprietary data to be published
after peer review.").
6. See Jeremy A. Colby, An Analysis of Genetic Discrimination Legislation Proposed by the
105th Congress, 24 AM. J.L. & MED. 443, 443-44 (1998) ("[G]enetic information may also result in a
world characterized by genetic discrimination and genetic determinism. Although genetic information
will be used to develop revolutionary treatments, such as gene therapy and other molecular medicine, it
will also bring genetic discrimination and heretofore unrealized invasions into the privacy of our
genetic codes.").
7. See Eliot Marshall, Sharing the Glory, Not the Credit, 291 SCI. 1189, 1191 (2001) (reporting
the stern reaction by scientists to the negotiations between Celera and Science of "a balanced plan,
requiring Celera to release data freely to academics but allowing the company to protect its database by
requiring readers to obtain access at a company site and register as academic or commercial users.").
Of course, the U.S. patent system has supporters and detractors alike. Nevertheless, its significance,
positive or negative, to the business community appears clear. See John R. Allison & Mark A. Lemley,
Who's Patenting What? An Empirical Exploration of Patent Prosecution, 53 VAND. L. REv. 2099, 2100
(2000) ("Patents are big business. Individuals and companies are obtaining far more patents today than
ever before. Some simple calculations make it clear that companies are spending over $5 billion a year
obtaining patents in the U.S.- to say nothing of the costs of obtaining patents elsewhere, and of
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principally the U.S. Court of Appeals for the Federal Circuit,8 and the U.S. Patent
and Trademark Office have both attempted to provide guidance on the intellectual
property rights that might impact such matters involving the human genome and
other genetic data. These efforts, however, have met with lackluster support at
best from patent law practitioners and other commentators, as well as the general
public.9
In recent days, public debate in this regard has focused on the proper scope, if
any, of general patent protection for genetic discoveries, and specifically for
expressed sequence tags and single nucleotide polymorphisms. Two concerns
prevail. The first relates to the challenge, pursuant to the written description
requirement of the patent law, to patent coverage of inventions pertaining to genes
or gene fragments where the applicant has failed to disclose the corresponding
nucleotide sequence information. The second involves whether isolated and
purified nucleic acid fragments with no known association or other functionality
can satisfy the patent law requirement of utility as well as written description.
Given the reactive nature of the patent system, particularly in a technical art
such as biotechnology where the law today deals with the potentially decades-old
science, the legal issues have centered on early research work in recombinant
protein production and genomics. 1° With the human genome sequence in hand,
scientists and other interested members of the public recognize that the practical
applications will likely include better, faster, cheaper routes to drug discovery and
licensing and enforcing the patents. There are a number of reasons why patenting is on the rise;
primary among them are a booming economy and a shift away from manufacturing and capital-
intensive industries towards companies with primarily intellectual assets. But whatever the reason, it is
evident that many companies consider patents important.").
8. The Federal Circuit has exclusive jurisdiction of appeals in civil actions across the country that
arise under the patent statutes. See 28 U.S.C. § 1295 (1994) (vesting the Federal Circuit with exclusive
jurisdiction in patent appeals from final judgments and orders of the U.S. district courts and the U.S.
Court of Federal Claims, from decisions of the Board of Patent Appeals and Interferences of U.S. Patent
and Trademark Office, from decisions of Commissioner of Patents and Trademarks, and from decisions
of the U.S. International Trade Commission); see also S. REP. No. 275, 97th Cong., 2d Sess. 2 (1981),
reprinted in 1982 U.S.C.C.A.N. (96 Stat.) 11, 12 (describing the legislative rationale behind the
establishment of the Federal Circuit with the enactment of the Federal Courts Improvement Act of
1982, Pub. L. No. 97-164, 96 Stat. 25, 37 (codified as amended at 28 U.S.C. § 1295)).
9. See Jerry Knight, Biotech Stocks Tougher to Unravel than Genome, WASH. POST, Feb. 19,
2001, at E01, 2001 WL 2545185, (warning about investment in biotechnology companies because
"[t]heir science is so complex, their business strategies so unpredictable, their path to profitability so
uncertain-to say nothing of so long-that it's impossible to calculate what each stock is worth or which
is better to buy.").
10. See Courtney J. Miller, Patent Law and Human Genomics, 26 CAP. U. L. REV. 893, 894 (1997)
("The genomics industry is a complex and frustrating combination of philanthropy and commercialism,
science and law. The basic premise of sequencing the human genome is that such a venture will benefit
humankind, but the importance of protecting the significant financial and physical investments required
to sustain the effort have resulted in the need for definitive federal legislative guidelines concerning the
intellectual property generated as the genomics industry matures.").
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advances in medical practice." However, a sobering reality has emerged as to how
daunting the magnitude of this task might truly be.
When it comes to human genetic makeup, there is an incredible amount of
chaff to separate from the wheat. Thus, how quickly medical researchers achieve
their goals may depend on how long it takes to understand the exploding
storehouses of genetic information. The true race now appears not to have been
who first maps every last stretch of human DNA, but who can most successfully
identify candidates for effective drug and gene therapy based on genetic
information with little, if any, known biological significance.
This progress depends in large part on other scientific fields, that of
bioinformatics (once better known as computational biology) and proteomics. 12
The legal ramifications of intellectual property protection in this developing
research area will probably take years to manifest, but might engender as much, if
not more, public debate as that which presently surrounds biotechnology patents.
13
Possibly compounding the problem will be the likely overlap in patentability
concerns with computer software programs at the heart of bioinformatics and
11. See Sara Dastgheib-Vinarov, A Higher Nonobviousness Standard for Gene Patents: Protecting
Biomedical Research from the Big Chill, 4 MARQ. INTELL. PROP. L. REV. 143, *158-59 (2000), WL 4
MARQIPLR 143 ("In the new millennium, computational and molecular techniques allow scientists to
accomplish what was once deemed impossible. Some of these techniques include designing optimum
DNA probes for PCR and comparing three-dimensional protein secondary structure of various species
with their mRNA sequences on a computer. These techniques, which reduce experiment times from
days to minutes, have made most traditional molecular biological procedures obsolete.").
12. See Mark J. Stewart, The Written Description Requirement of 35 U.S.C. § 112(1): The
Standard after Regents of the University of California v. Eli Lilly & Co., 32 IND. L. REV. 537, 555 n. 153
(1999) ("The development of bioinformatics is beginning to manage the increasing amount of genetic
sequence information that is becoming available. Bioinformatics provides ways to analyze DNA and
protein sequences and make predictions regarding structure or function relationships.") (citing Andreas
D. Baxevanis & B.F. Ouellette, BIOINFORMATICS: A PRACTICAL GUIDE TO THE ANALYSIS OF GENES
AND PROTEINS (lst ed. 1998)); Ronald Cass et al., Advances in Biomaterials and Devices, and Their
Financing, 6 B.U. J. SCI. & TECH. L. 2, *23 (2000) WL 6 BUJSTL 2, ("How bioinformatics and genetic
engineering become important is that one can use information from the human genome project. The
idea is then to use this information to help predict what functions other proteins or other regions of
proteins are involved in-not only cellular adhesion but also other cellular roles such as cell death,
growth, and migration and differentiation."); David Malakoff & Robert F. Service, Genomania Meets
the Bottom Line, 291 SCI. 1193, 1201 (2001) ("Toolmakers, information suppliers, and discovery
companies are already looking beyond genomics to proteomics, the latest effort to demystify the
functions of the proteins coded for by all those genes. Surveying genes is a good way of finding
possible drug targets, the reasoning goes."); Stanley Fields, Proteomics in Genomeland, 291 SI. 1221,
1221 (2001) ("In the wonderland of complete sequences, there is much that genomics cannot do, and so
the future belongs to proteomics: the analysis of complete complements of proteins.").
13. See Lawrence M. Sung & Jeff E. Schwartz, Patent Law: Business Method Defense, NAT'L L.J.,
Apr. 10, 2000, at B8, available at WL 4/10/00 NLJ B8, (col. 1) ("[W]hen the U.S. Court of Appeals for
the Federal Circuit issued its decision in State Street Bank & Trust Co. v. Signature Financial Group
Inc., 149 F.3d 1368 (Fed. Cir. 1998), cert. denied, 525 U.S. 1093 (1999), the patent law changed to
recognize business methods, for the first time, as patentable subject matter .... [B]usiness method




proteomics applications with the potential for characterization as business
methods. 14
II. PUSHING THE LIMITS OF THE PATENT REGULATORY REGIME: THE LEGAL,
ACADEMIC, AND SOCIAL IMPLICATIONS OF EMERGING TECHNOLOGIES
Recently, real-world events have heightened the importance of the
intersection between genomic sequencing determinations and bioinformatics
technology. For example, prior to September 11, 2001, the Institute for Genomic
Research had generally committed its resources to the elucidation of various
organisms. 15 However, the Institute's resources have since been retasked to focus
on determining the genomic sequence of the possible bioterrorist weapon, Bacillus
anthracis, the causative agent of anthrax.16 Despite its tragic toll, the anthrax scare
unwittingly revealed the powerful capabilities currently available in genomics and
bioinformatics.
This rapid innovation in the genetic arts in turn demands careful
consideration of both patent laws and regulations that are implicated by emerging
technological discoveries. This examination is particularly important because the
technologies involved in genomics and bioinformatics will likely stretch the
applicability of the patent regulatory regime well beyond initially contemplated
purposes.
14. See Rebecca S. Eisenberg, Genetics and the Law: The Ethical, Legal, and Social Implications
of Genetic Technology and Biomedical Ethics: Intellectual Property at the Public-Private Divide: The
Case of Large-Scale cDNA Sequencing, 3 U. CHI. L. SCH. ROUNDTABLE 557, *564-65 (1996), WL 3
UCHIRLSRT 557:
Despite the growth of the public database, the private databases remain significantly larger. Inasmuch
as all the information that enters the public database promptly becomes available in the private
databases as well, the public database can never contain more information than the private databases.
The private database owners also claim to offer superior products in that they have assembled
contiguous fragments into longer sequences, they provide more complete annotations for the sequences,
including information about expression in different types of tissue, they provide sequence information
from customized cDNA libraries derived from tissue types of interest to their subscribers, and their
sequence information comes with high-powered bioinformatics capabilities and user-friendly software.
Ironically, Merck's investment in enhancing the public database may have enhanced the value of the
private databases as a resource for discovery, not only by contributing further data to make the
information in the private databases more complete, but also by creating a deluge of information that
enhances the value of the complementary proprietary bioinformatics capabilities that the private
database owners offer to their clients. Id. (internal citations omitted).
15. Videotape: Dr. Steven L. Salzberg, Keynote Address: Genomics in the 21st Century:
Forensics, Pathogens, and Genetics, at At the Crossroads-Public/Private Priorities Concerning Access
to Genetic Information, Tape I of 4 (Oct. 21, 2002) (on file with the University of Maryland School of
Law, Thurgood Marshall Law Library).
16. See generally id.
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Moreover, attempts to obtain patent protection for early stage research
products may negatively impact scientific progress.' 7 Indeed, in view of their
fledgling nature, some of these inventions might carry little or no attendant
knowledge about their practical utility.' 8 The notion of according patent rights in
these instances seemingly would contravene the goal of the patent system to allow
exclusivity only when the public obtains the benefit of significant learning
regarding an innovative technology.' 9 Janice Mueller, one of the contributors to
this edition, invites us to examine the tension between constructing patent
protection for bioinformatics technologies and ensuring public access to
technologies that may possess invaluable public welfare benefits.
20
Given the rapidity with which technology will be available to affect whole
genomic sequencing over the next decade, new models must also emerge to engage
these capabilities within the health care regime, and to guard against exploitation
by those "with access" to the detriment of the individual. For example, how
should new genetic screening capabilities be utilized by health insurers? Drs. Levy
and Lawler present a model for health insurance in which screening guidelines are
customized to the individual policy holder, delivering superior health care, and yet
maintaining profitability for the insurer.2'
In addition to the complex issues of access stemming from the patentability
of emerging biotechnology applications, are those issues surrounding technology
transfer. Under the statutory scheme established by the Bayh-Dole Act,
22
academic institutions may elect to retain title to inventions created in the course of
federally funded research.23 These organizations may choose to exploit such
inventions by seeking patent protection and licensing this intellectual property to
the private sector for commercial development. Furthermore, it is important to
note that unlike the laws governing copyrights and trademarks, patent law provides
no exemption for academic research similar to the doctrine of fair use.
24
17. Videotape: Dr. Francis S. Collins, Address at At the Crossroads-Public/Private Priorities
Concerning Access to Genetic Information, Tape 2 of 4 (Oct. 21, 2002) (on file with the University of
Maryland School of Law, Thurgood Marshall Law Library).
18. See generally id.
19. Id.
20. See generally Janice M. Mueller, Public Access Versus Proprietary Rights in Genomic
Information: What is the Proper Role of Intellectual Property Rights?, 6 J. HEALTH CARE L. & POL'Y
222 (2003).
21. See generally Frederick Levy & Joseph F. Lawler, The Potential Impact of Genetic Sequencing
on the American Health Insurance System?, 6 J. HEALTH CARE L. & POL'Y 203 (2003).
22. 35 U.S.C.S. § 203 (2000).
23. Videotape: Second panel discussion moderated by Mary S. Webster, Assistant Professor of
Law and Director of the Maryland Intellectual Property Legal Resource Center, at At the Crossroads-
Public/Private Priorities Concerning Access to Genetic Information, Tape 2 of 4 (Oct. 21, 2002) (on file
with the University of Maryland School of Law, Thurgood Marshall Law Library).
24. My personal contribution to this edition discusses the future of a research use exemption from
patent infringement liability. See Lawrence M. Sung & Claire M. Maisano, Piercing the Academic
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In order to gain an appreciation for the effect of intellectual property rights on
the collegiality and collaboration behaviors of researchers working in the trenches
of innovation, information must be captured and analyzed regarding the attitudes
and policies of research institutions regarding technology transfer. Although
openness in data-sharing in academic research is a fundamental norm underlying
the social structure of academic science, the commercialization of university
research through technology transfer has somewhat chilled this openness.25
This edition also provides unique insight into the conflicting attitudes and
policies of researchers and academic institutions regarding data-sharing and
withholding. Drs. Eric G. Campbell and Eran Bendavid at the Institute for Health
Policy at the Massachusetts General Hospital unveil the results of a landmark
national survey of the senior technology transfer officials of the one hundred most
research-intensive universities.26 Of particular note is the lack of consensus among
technology transfer officers toward data-sharing and withholding, which the
authors note may be a result of conflicting pressures brought to bear on these
officers.2 7
The diversity in attitudes among technology transfer officers is but a
microcosm of the wide-ranging spectrum of societal views regarding the moral,
social and ethical implications of patent exclusivity and use of genetic
knowledge.28 Our two student contributors to this edition engage these social
implications, but in differing ways: where one analyzes the spectrum of moral and
social considerations in determining they should not impede exclusivity; 29 the
other provides a critique of Leon R. Kass' 2002 book, Life, Liberty and the
Defense of Dignity: The Challenge for Bioethics, reminding us that even in the
absence of new regulatory and legislative constraints on the use of genetic
information, the scientific community has refrained from recklessly unleashing
new technologies.
30
Veil: Disaffecting the Common Law Exception to Patent Infringement Liability and the Future of a
Bona Fide Research Use Exemption after Madey v. Duke University, 6 J. HEALTH CARE L. & POL'Y
256 (2003).
25. See Eric G. Campbell & Eran Bendavid, Data-Sharing and Data-Withholding in the Genetics
and Life Sciences: Results of a National Survey of Technology Transfer Officers, 6 J. HEALTH CARE L.
& POL'Y 241 (2003).
26. See generally id.
27. Id.
28. Videotape: Third panel discussion, moderated by Barbara Fuller, Chief of Policy, Education
and Outreach at the National Human Genome Research Institute, at At the Crossroads-Public/Private
Priorities Concerning Access to Genetic Information, Tape 3 of 4 (Oct. 21, 2002) (on file with the
University of Maryland School of Law, Thurgood Marshall Law Library) (discussing the ethical and
social implications of exclusivity in genetic knowledge).
29. See generally Amanda Pitcher, Genes Are Patentable, Contrary to First Impression: Should
There Be Limitations?, 6 J. OF HEALTH CARE L. & POL'Y 284 (2003).
30. See generally Ella Judge Hayes, Biotechnology and Human Dignity, A Neessary and
Compatible Union, 6 J. HEALTH CARE L. & POL'Y 304 (2003).
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III. SEEKING BALANCE: UNFETTERED ACCESS VERSUS THE PROTECTION OF
INVESTMENT-BACKED EXPECTATIONS
In recent days, the perception of intellectual property rights as the driving
force of creativity, innovation, and knowledge exchange seems to have lost its
luster among the general public. Among those who have a more direct
involvement with patent rights, the situation might be no more settled. Patent
rights, for example, appear under routine attack- at best as disreputable rent
seeking measures and at worst as obstacles themselves to true scientific
advancement.
Of course, the ingenuity of a patent system lies with the optimization of
social benefit from grants of limited exclusivity. But little disagreement appears to
exist that the actual attainment of the proper balance between providing unfettered
access and securing investment-backed expectations to new technologies is an
illusive matter. The conference, "At the Crossroads-Public/Private Priorities
Concerning Access to Genetic Information," was born from the inspiration to
engage interdisciplinary perspectives on contemporary social, economic and
political realities with regard to biotechnology research and development. Perhaps
the success of such a forum lies with the questions raised as much as the answers
provided. The University of Maryland School of Law is proud to play a role in
enhancing the dialogue in both respects.
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